These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26713838)

  • 21. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.
    Elsässer D; Stadick H; Stark S; Van de Winkel JG; Gramatzki M; Schrott KM; Valerius T; Schafhauser W
    Anticancer Res; 1999; 19(2C):1525-8. PubMed ID: 10365137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 23. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
    Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
    J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Therapies: Bevacizumab and interferon-alpha in metastatic renal-cell carcinoma.
    Bukowski RM
    Nat Rev Clin Oncol; 2009 May; 6(5):253-4. PubMed ID: 19390549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of metastatic renal cell carcinoma].
    Thuret R; Maurin C; Sun M; Perrotte P; Karakiewicz PI
    Prog Urol; 2011 Apr; 21(4):233-44. PubMed ID: 21482396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
    J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
    Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
    Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma.
    Mickisch GH
    Eur Urol; 2003 Jun; 43(6):670-9. PubMed ID: 12767369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
    Doehn C; Jocham D
    Aktuelle Urol; 2004 Apr; 35(2):121-9. PubMed ID: 15146376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?
    Oliver RT
    Br J Cancer; 1998 Apr; 77(8):1318-20. PubMed ID: 9579839
    [No Abstract]   [Full Text] [Related]  

  • 34. Renal cancer immunotherapy: a ray of hope or regression to the mean?
    Stadler W
    Cancer Invest; 2000; 18(5):490-1. PubMed ID: 10834033
    [No Abstract]   [Full Text] [Related]  

  • 35. Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).
    Pandha H
    Integr Cancer Ther; 2004 Mar; 3(1):29-34. PubMed ID: 15035872
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunotherapy of metastatic renal cell cancer.
    Fishman M; Seigne J
    Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
    Gore ME; Griffin CL; Hancock B; Patel PM; Pyle L; Aitchison M; James N; Oliver RT; Mardiak J; Hussain T; Sylvester R; Parmar MK; Royston P; Mulders PF
    Lancet; 2010 Feb; 375(9715):641-8. PubMed ID: 20153039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nephrectomy for metastatic renal-cell cancer.
    Copur MS; Ledakis P; Norvell M
    N Engl J Med; 2002 Apr; 346(14):1095-6. PubMed ID: 11936126
    [No Abstract]   [Full Text] [Related]  

  • 39. [Medical treatment of renal cell carcinoma].
    Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G
    Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New treatment approaches for metastatic renal cell carcinoma.
    Nanus DM
    Curr Oncol Rep; 2000 Sep; 2(5):417-22. PubMed ID: 11122873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.